Clinical Data REGENXBIO slumps after serious side effects mar Duchenne gene therapy results BioSpaceShares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call Thursday.Gene Therapy PlatformRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) BioSpace Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company’s first quarter earnings call Thursday. Gene Therapy Platform Read full story Post navigation Previous: Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimismNext: Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drug Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026